Researchers have found that adults who stop taking GLP-1 receptor agonist drugs such as semaglutide and tirzepatide face a measurable increase in heart attack, stroke, and death risk within months of discontinuation. The findings, drawn from real-world U.S. health records, challenge the assumption that cardiovascular benefits from these popular medications persist after patients quit. With millions of Americans cycling on and off GLP-1 drugs due to cost, supply shortages, and side effects, the data raise pointed questions about what happens to heart health when treatment ends.
How Quickly Heart Protections Fade
A retrospective cohort study published in the European Heart Journal tracked new adult users of injectable semaglutide or tirzepatide with a BMI of 27 or higher, identified through U.S. electronic health records spanning more than 20,000 clinics and 700 hospitals across 43 states. The study period ran from July 1, 2022, to December 31, 2024, and defined discontinuation as a gap of 90 days or more after the last prescription. According to the analysis, patients who stopped treatment experienced higher rates of major adverse cardiovascular events in the year following discontinuation compared with those who remained on therapy, even after accounting for baseline health differences.
Separate research from Washington University School of Medicine sharpened the timeline. In a report by investigators at that institution, summarized by university communications, even brief interruptions in GLP-1 therapy were tied to changes in the risk of heart attack, stroke, and death. The longer the gap in treatment, the bigger the jump in risk, reaching up to a 22% increase in major cardiovascular events after two years off the drugs. That dose-response pattern, where longer gaps produce worse outcomes, strengthens the case that the connection is not random noise in the data but reflects the loss of a protective effect once treatment stops.
These studies were observational, meaning they cannot prove causation with the same confidence as randomized clinical trials. Patients who discontinue medication may differ in important ways from those who continue, including in their underlying health, access to care, or adherence to other therapies. Still, the consistency of the findings across large data sets, and the clear gradient of risk with longer discontinuation, has prompted cardiologists and endocrinologists to reconsider earlier assumptions about how long GLP-1–related heart benefits last.
The FDA Already Bet on Lasting Heart Benefits
The new discontinuation findings land against a regulatory backdrop that assumed patients would stay on therapy for extended periods. The U.S. Food and Drug Administration recently granted a cardiovascular-risk–reduction indication to Wegovy, the higher-dose semaglutide formulation, to reduce cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. That decision was based on a large outcomes trial of more than 17,600 participants who showed fewer cardiac events while actively taking the medication compared with placebo.
However, clinical trials typically track what happens when patients take medications as directed under close supervision, with structured follow-up and strong support for adherence. The real world operates differently. Insurance coverage can change, copays can rise, and pharmacy shortages can interrupt supply. The gap between trial-proven benefit and actual patient experience is where the discontinuation data become uncomfortable. If the heart protections that justified the FDA’s expanded label diminish quickly after patients stop, the long-term public health value of that indication depends heavily on whether people can afford and access continuous treatment over many years.
Regulators and clinicians now face a nuanced question: Are GLP-1 drugs best understood as long-term, possibly lifelong cardiovascular therapies, akin to statins, or as time-limited interventions primarily for weight loss? The emerging evidence suggests that, at least for heart protection, these medications behave more like chronic treatments whose benefits fade when the drug is withdrawn.
Most Patients Do Not Stay on GLP-1 Drugs
Persistence rates tell a sobering story about how difficult it is to sustain GLP-1 therapy in practice. A retrospective cohort study of 125,474 adults who initiated liraglutide, semaglutide, or tirzepatide between January 1, 2018, and December 31, 2023, using U.S. health-system electronic health record data from the Truveta collective, found that 64.8% of adults without type 2 diabetes discontinued within one year. Among those with type 2 diabetes, the one-year discontinuation rate was 46.5%. In other words, roughly half to two-thirds of patients stopped treatment before completing a full year of therapy.
These numbers reflect a system-level problem more than individual failure. Monthly costs for brand-name GLP-1 drugs can exceed $1,000 without robust insurance coverage, making long-term use financially out of reach for many households. Supply constraints have periodically forced pharmacies to ration doses or substitute different formulations. Side effects, particularly nausea, vomiting, and other gastrointestinal symptoms, prompt some patients to quit or take “drug holidays” that may inadvertently raise cardiovascular risk. And unlike blood pressure medications that have been generic for decades, GLP-1 receptor agonists remain expensive branded products with limited lower-cost alternatives.
Even in cardiology and endocrinology clinics that care for the highest-risk patients, persistence is a challenge. Separate research in U.S. specialty practices has reported substantial discontinuation among people with type 2 diabetes and atherosclerotic cardiovascular disease, underscoring that specialist oversight alone does not guarantee long-term adherence. For many patients, the choice is not between ideal continuous use and reckless nonuse, but between intermittent treatment and none at all.
Weight Regain as a Cardiovascular Mechanism
One plausible explanation for why heart risks climb after stopping GLP-1 drugs is weight regain. A systematic review and meta-analysis examining body composition changes after GLP-1 discontinuation reported pooled mean regain values for liraglutide, semaglutide, and tirzepatide, confirming that patients tend to recover a significant portion of the weight they initially lost once they stop the medications. In many cases, the rebound includes increases in both fat mass and, to a lesser extent, lean mass, effectively reversing much of the cardiometabolic progress achieved during treatment.
That weight rebound does not happen in isolation. Regained adipose tissue is associated with higher blood pressure, worsening blood sugar control, unfavorable cholesterol shifts, and heightened inflammatory activity, all of which feed directly into cardiovascular risk. For people with existing heart disease or multiple risk factors, a rapid return of weight can translate into more frequent angina, reduced exercise tolerance, and a higher likelihood of heart attack or stroke over time.
There is also concern about weight cycling, the pattern of losing and regaining substantial amounts of weight repeatedly. Earlier research outside the GLP-1 context has linked weight cycling to metabolic stress, including insulin resistance and dyslipidemia, that may exceed the risk of stable obesity at a constant weight. If GLP-1 drugs produce dramatic weight loss followed by equally dramatic regain when patients stop, the net cardiovascular effect for those who cannot maintain therapy could be smaller than expected, or, in some scenarios, potentially harmful, though current data have not conclusively demonstrated that outcome.
What Patients and Clinicians Can Do Now
For patients already taking GLP-1 medications, the emerging evidence argues for viewing these drugs as long-term tools rather than short-term fixes. Abruptly stopping therapy without a plan for maintaining weight loss and cardiometabolic control may carry real risks. Clinicians may want to discuss continuity of care early, including insurance coverage, potential dose adjustments to manage side effects, and backup strategies if supply problems arise.
Shared decision-making is critical. Some patients may reasonably prioritize short-term weight loss to qualify for surgery or meet other time-limited goals, accepting the possibility of later weight regain. Others, particularly those with established cardiovascular disease, may decide that the potential heart benefits justify a long-term commitment if they can secure stable coverage. In both cases, transparent conversations about the likelihood of discontinuation and its consequences can help avoid unintended harm.
Patients and clinicians who suspect serious side effects or unexpected cardiovascular events associated with GLP-1 drugs can report them through the federal safety reporting portal, which feeds into national surveillance systems. Such reports, combined with ongoing observational research, will help refine understanding of how these medications perform outside trial settings and inform future guidance on initiation and discontinuation.
For now, the message from real-world data is less about miracle cures and more about trade-offs. GLP-1 receptor agonists can deliver meaningful cardiovascular protection while patients are taking them, but those benefits appear closely tied to continued use. In a health system where many people cannot stay on these drugs for financial or practical reasons, the challenge will be ensuring that the promise of better heart health does not evaporate the moment the prescription runs out.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
